Key Takeaway: Dr. Jason Funt, Ph.D., specializes in synthesizing insights from complex data. He obtained his Ph.D. in Computational and Systems Biology from MIT, where his research centered on understanding drug resistance in the pathogen Candida albicans through genomic and transcriptomic profiling.
Price reaction · baseline $6.73 (2025-12-26 close) · 32 other IMRX headline(s) in the window, move may be shared
day 0 close · peak
-1%
Market Sentiment Analysis
POSITIVE FACTORS
Dr. Funt has a strong academic background from MIT.
His research focuses on actionable insights from complex data.
He has expertise in drug resistance mapping.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor
Full Press Release Details
Dr. Funt’s focus is in synthesizing actionable insight from complex, heterogeneous high-dimensional data. He earned his Ph.D. in Computational and Systems Biology from MIT’s Biology Department. His thesis research, at both the Massachusetts Institute of Technology and the Broad Institute, focused on mapping evolutionary pathways of drug resistance from genomic and transcriptomic profiling of the pathogen Candida albicans.
Frequently Asked Questions
What is Dr. Jason Funt's area of expertise?
Dr. Funt specializes in synthesizing insights from complex, high-dimensional data.
Where did Dr. Funt earn his Ph.D.?
He earned his Ph.D. in Computational and Systems Biology from MIT.
What was the focus of Dr. Funt's thesis research?
His research focused on mapping evolutionary pathways of drug resistance.